GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE TO CROSS USD 24 BILLION BY 2025, GROWING AT A CAGR OF 7% DURING THE FORECAST PERIOD

Infectious Disease Diagnostics Market Size, Share, Trends, Analysis Report by Product (Instruments/Analyzers and Software and Consumables), Disease (Hepatitis, AIDS, HAIs, Influenza, Tuberculosis, Malaria, HPV Infection, Sepsis, Dengue, and Other Diseases), End-users (Hospitals, Standard Reference Laboratories, Public Health Laboratories, Blood Banks, Acute Care Settings, and Others), Test (Traditional Diagnostics and Molecular Diagnostics), and Geography (APAC, Europe, North America, Latin America, and Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Trends, Competitive Landscape, Share & Forecast, 2020–2025

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Customize this Report

Most Exhaustive Report

282 Pages

151 Tables

47 Charts

5 Regions

18 Countries

24 Companies

5 Market Segment

GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET REPORT SCOPE

Report Attribute Details
Market Size (REVENUE) USD 24 Billion (2025)
CAGR 7% (2020-2025)
Base Year 2019
Forecast Year 2020-2025
Market Segments Product (Instruments/Analyzers and Software and Consumables), Disease (Hepatitis, AIDS, HAIs, Influenza, Tuberculosis, Malaria, HPV Infection, Sepsis, Dengue, and Other Diseases), End-users (Hospitals, Standard Reference Laboratories, Public Health Laboratories, Blood Banks, Acute Care Settings, and Others), Test (Traditional Diagnostics and Molecular Diagnostics)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered US, Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, Australia, India, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, and Turkey

INDUSTRY INSIGHTS

The global infectious disease diagnostics market size to cross USD 24 billion by 2025, growing at a CAGR of over 7% during the forecast period. The global infectious disease diagnostics market, which is one of the major segments in the global in-vitro diagnostics market, is likely to grow at a steady rate during the forecast period. The growth can be attributed to the growing prevalence/incidence of several infectious diseases. Malaria continues to be a major cause of death in the Middle East and Africa. The market is witnessing growth due to the increase in the usage of diagnostic tests for several purposes, including routine health checkups, infectious diseases, seasonal flu. Improvements in technology such as the introduction of automated analyzers, advanced devices with high throughput with reduced waiting time and point-of-care diagnostics, and the ability to perform a large volume of tests in a shorter duration of time are fueling the growth of the infectious disease diagnostics market across the globe.

SNIPPETS

  • The molecular segment is expected to grow at the highest CAGR of over 10% during the period 2019­–2025 due to the increased revenue contribution of polymerase chain reaction (PCR) technology.
  • The hospital-acquired infections (HAIs) segment is likely to reach over $9 billion by 2025. The usage of diagnostic tests to diagnose several HAIs is considered as an important step to initiate several preventive measures. 
  • The consumable segment is likely to observe an incremental growth of over $7 billion by 2025 on account of the increasing sale of high-end instruments by hospitals, commercial labs, and other facilities. 
  • The standard reference laboratories segment is projected to over $8 billion by 2025, owing to the rise of private laboratories, especially in developing countries. 
  • The infectious disease diagnostics market in India is likely to grow at a CAGR of over 8% during the period 2019­­–2025 on account of the rapidly growing patient pool with infectious diseases and increased market access.

 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Products
  • Disease
  • End-user
  • Tests
  • Geography

INSIGHTS BY TEST

In 2019, the traditional diagnostics segment accounted for 66% of the infectious disease diagnostics market share. The segment is growing at a moderate rate than molecular diagnostics. Conventional diagnostics include immunodiagnostics, blood culture tests, and clinical, microbiological methods to diagnose several diseases. However, the molecular segment is rapidly capturing the revenue share of the traditional segment. Molecular diagnostic tests are based on DNA amplification techniques. They have comparatively higher sensitivity and specificity than immunoassays. Most tests are based on real-time PCR. However, these tests are comparatively complicated and expensive.

INSIGHTS BY DISEASE 

Tuberculosis (TB) segment is expected to be one of the major revenue contributors by 2025. By the end of 2018, around 10 million people were infected with TB, including 5.7 million men, 3.2 million women, and 1.1 million children. Therefore, the increasing burden of TB disease across the world, especially in India, China, South Africa, and Bangladesh constituting a significant percentage of TB cases, is likely to influence the segment growth.

The hepatitis segment is likely to grow at a CAGR of over 4% during the period 2019–2025. The staggering rise in liver damage cases due to viral infections, drug, and chemical abuses, and an increase in alcohol intake, is contributing to the growth of the segment. The presence of a high pool of infected patients who are undiagnosed and need urgent diagnosis is another driver influencing the segment growth. 

Improvements and enhancements in infectious disease testing methods for HIV testing is a major driver for the segment growth. Conventional methods for HIV testing, based on the detection of HIV-specific antibodies, have been improved over time, gaining in sensitivity and specificity. Kits that allow simultaneous determination of both HIV-specific antibodies and the p24 antigen have been recently introduced, thereby increasing the demand. There is a widespread concern of adverse effects of hospital-acquired infections (HAIs), which are increasing the market share of the Healthcare-associated Infections Diagnostics Market.  Healthcare providers and vendors are actively engaged in providing an expedited diagnosis of HAIs for quick clinical decision-making to support treatment regimens.

INSIGHTS BY END-USER  

The hospital end-user segment dominated the infectious disease diagnostics market shares. It accounted for the highest market share of over 34% in 2019 due to the high volume of infectious disease diagnosis and treatment performed in these settings. The increase in the number of private hospitals, which have their central laboratories performing a high volume of tests, is a major factor influencing the market growth. Standard reference laboratories accounted for a share of 33% share. The number of standard reference laboratories (both private and public run labs) is increasing in large cities and urban areas of developing countries and developed countries due to an increase in epidemic conditions and the rise in prevalence of several infectious diseases such as malaria, dengue, and HIV. The demand for diagnosis is higher and plays a vital role in preventing the spread of acute diseases and take immediate preventive measures as well as help in making critical clinical decisions regarding treatment regimens. Public health laboratories accounted for a share of 12% in the end-user segment.

INSIGHTS BY PRODUCT

In 2019, the consumables segment accounted for 74% of the global infectious disease diagnostics market shares. The increasing share of consumables is due to the usage of a wide array of several standard reagents and test kits to perform various tests catering to the need of end-users. The usage of consumables is reoccurring in nature, and the consumables segment generates continuous revenue for vendors.

The instruments/ analyzers segment includes the capital equipment such as analyzers, test kit, assay instruments used for performing the routine as well as specialized tests. However, with advances in technology, vendors are offering highly automated and semi-automated analyzers, which are replacing conventional testing methods. As the lifespan of analyzers is higher, they do not require repetitive purchases. The sale of the latest instruments /analyzers is higher in developed countries than developing and under-developing countries due to the economic factors impacting the purchase of the advanced, costly equipment for the analysis.

INSIGHTS BY GEOGRAPHY

APAC is expected to grow at the highest CAGR of over 8% during the period 2019–2025. The region is witnessing the highest growth rate due to the high prevalence of infectious diseases in countries such as China, India, Japan, Australia, and South Korea. It is home to more than half of the world’s population, and the bulk of this population is still hugely underserved. The region is made up of diverse countries with varying needs. There are certain countries whose healthcare segment is developed, and a few countries’ healthcare systems are still in infancy. However, the diagnostics market will have a high growth rate in this region due to the increase in infectious disease, combined with the aging population, which has put immense pressure on the healthcare resources in the region.

INSIGHTS BY VENDORS

The global infectious disease diagnostics industry is highly dynamic, with the presence of several global and local players offering a diverse range of instruments/analyzers and reagents. Abbott, BD, bioMérieux, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche, Luminex, Quidel, and Thermo Fisher Scientific are the leading players and accounted for significant shares in the market. Global players are focusing on developing innovative products and expanding their product portfolio to remain competitive in the market. They are investing extensively in R&D and product development activities to expand their product portfolio.

The global infectious disease diagnostics market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

 By Products 

  • Instruments/ Analyzers and Software
  • Consumables

By Disease   

  • Hepatitis
  • AIDS
  • HAIs
  • Influenza
  • Tuberculosis
  • Malaria
  • HPV Infection
  • Sepsis
  • Dengue
  • Other Diseases

By End-user  

  • Hospitals
  • Standard Reference Laboratories
  • Public Health Laboratories
  • Blood Banks
  • Acute Care Settings
  • Others

By Test

  • Traditional Diagnostics
  • Molecular Diagnostics

 By Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • APAC
    • China
    • Japan
    • South Korea
    • Australia
    • India
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey
    • Iran

Frequently Asked Questions

Infectious disease diagnostics market size to cross $24 billion by 2025, growing at a CAGR of over 7% during the forecast period
The market is witnessing growth due to the increase in the usage of diagnostic tests for several purposes, including routine health checkups, infectious diseases, seasonal flu.
In 2019, the traditional diagnostics segment accounted for 66% of the infectious disease diagnostics market share.
Abbott, BD, bioMérieux, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche, Luminex, Quidel, and Thermo Fisher Scientific are the leading players and accounted for significant shares in the market.
The hospital end-user segment accounted for the highest market share of over 34% in 2019 due to the high volume of infectious disease diagnosis and treatment performed in these settings
Read More

Select a license type that suits your business needs

Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$4000.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Select a license type that suits your business needs

Best Value Tag
Coming Soon
  • Stay tuned with us.

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

Our Clients

Licence Types What are these?

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date